World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
167
Citations
179491
World Ranking
575
National Ranking
334

Research.com Recognitions

  • 2020 - Member of the National Academy of Medicine (NAM)

Overview

Antoni Ribas is affiliated with the University of California, Los Angeles in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a strong focus on Oncology, Molecular Biology, and Immunology. Their work contributes extensively to Cancer Research and Radiology, Nuclear Medicine, and Imaging.

The main topics of their research include Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Melanoma and MAPK Pathways, Immunotherapy and Immune Responses, Cutaneous Melanoma Detection and Management, Immune Cell Function and Interaction, and Cancer Genomics and Diagnostics.

Among their frequent co-authors are Katie M. Campbell, Georgina V. Long, Caroline Robert, Egmidio Medina, and Paolo A. Ascierto. Over time, their research has been published repeatedly in several venues, notably Cancer Research, Journal of Clinical Oncology, Cancer Discovery, bioRxiv (Cold Spring Harbor Laboratory), and Clinical Cancer Research.

Recent publications include:

  • Multiple early factors anticipate post-acute COVID-19 sequelae, 2022, Cell
  • Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma, 2023, New England Journal of Medicine
  • Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction, 2020, Cell
  • Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134, 2022, Journal of Clinical Oncology
  • Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma, 2020, Cancer Cell

Their research contributions reflect a strong engagement with cancer immunotherapy, especially regarding melanoma treatment and immune response mechanisms.

Antoni Ribas is a member of the National Academy of Medicine (NAM), an award received in 2020.

Best Publications

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • PD-1 blockade induces responses by inhibiting adaptive immune resistance

    Paul C. Tumeh;Christina L. Harview;Jennifer H. Yearley;I. Peter Shintaku

  • Cancer immunotherapy using checkpoint blockade

    Antoni Ribas;Jedd D. Wolchok;Jedd D. Wolchok

  • Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Caroline Robert;Caroline Robert;Caroline Robert;Jacob Schachter;Georgina V. Long;Ana Arance

  • Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

    Alexandra Snyder;Vladimir Makarov;Taha Merghoub;Jianda Yuan

  • Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

    Padmanee Sharma;Siwen Hu-Lieskovan;Jennifer A. Wargo;Antoni Ribas

  • Inhibition of mutated, activated BRAF in metastatic melanoma.

    Keith T. Flaherty;Igor Puzanov;Kevin B. Kim;Antoni Ribas

  • Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi

  • IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade

    Mark Ayers;Jared Lunceford;Michael Nebozhyn;Erin Murphy

  • Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

    Jesse M. Zaretsky;Angel Garcia-Diaz;Daniel S. Shin;Helena Escuin-Ordinas

  • Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma

    Willy Hugo;Jesse M. Zaretsky;Lu Sun;Chunying Song

  • Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

    Mark E. Davis;Jonathan E Zuckerman;Chung Hang J Choi;David Seligson

  • Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski

  • Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez

  • Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

    Ramin Nazarian;Hubing Shi;Qi Wang;Xiangju Kong

  • Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

    James Larkin;Paolo A. Ascierto;Brigitte Dréno;Victoria Atkinson

  • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial

    Caroline Robert;Antoni Ribas;Jedd D. Wolchok;F. Stephen Hodi

  • Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma

    Gideon Bollag;Peter Hirth;James Tsai;Jiazhong Zhang

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

    Ravid Straussman;Teppei Morikawa;Kevin Shee;Michal Barzily-Rokni

Frequent Co-Authors

Georgina V. Long
Georgina V. Long University of Sydney
Caroline Robert
Caroline Robert University of Paris-Saclay
Grant A. McArthur
Grant A. McArthur Peter MacCallum Cancer Centre
Keith T. Flaherty
Keith T. Flaherty Harvard University
James S. Economou
James S. Economou University of California, Los Angeles
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Richard F. Kefford
Richard F. Kefford Macquarie University
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Adil Daud
Adil Daud University of California, San Francisco
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those considering a career in Medicine or healthcare, there are several flexible online degree options to support your journey. Nurses looking to specialize can explore psychiatric np programs, which prepare you for advanced practice in mental health and are often offered with fast-track online formats.

If you're interested in the administrative side of healthcare, pursuing healthcare administration degrees opens doors to management roles in hospitals, clinics, and public health organizations. Many institutions now offer affordable online options, making it easier to balance studies with professional commitments.

For those aiming higher, a masters in healthcare administration cost can be a concern, but numerous universities provide budget-friendly online programs. Similarly, registered nurses looking to advance their careers can consider the cheapest online bsn to dnp programs to gain the highest level of clinical nursing education and leadership skills.

These online degree pathways offer flexibility, affordability, and specialized training to help you progress in the ever-evolving healthcare sector.

Best Scientists Citing Antoni Ribas

Trending Scientists